When Lung Cancer Follows Lung Transplant—A Discussion on JHLT: The Podcast JHLT Digital Media Editors bring on guest Pauline Pradère, MD, of Hôpital Marie Lannelongue in Paris, to discuss lung cancer after lung transplantation, and the management of these complex patients.

What should clinicians know about #LungCancer after #LungTransplant?

It's today's topic on #JHLTThePodcast and the Digital Media Editors are joined by senior author Pauline Pradère from Hôpital Marie Lannelongue to discuss her paper in the April issue of #JHLT.

www.ishlt.org/about/news-d...

Early Experiences with Heart Transplant Using HIV+ Donors on JHLT The Podcast The first of two themed conversations around HIV in solid organ transplant by discussions a paper on heart transplant using HIV+ donors with Omar Saeed of Montefiore Medical Center in New York.

What happened when the Montefiore heart transplant program began using HIV+ hearts in HIV+ recipients? Omar Saeed shares results published this month in #JHLT that explore the survival of HIV+ recipients using both HIV-positive and HIV-negative donors. #cardiosky #IDsky
www.ishlt.org/about/news-d...

🚨 Submit your papers on primary graft dysfunction (#PGD) to #JHLT. 🫀🫁 Submissions will be accepted until 📆 28 February: 🔗 https://bit.ly/4r6vuog

#CallforPapers #HeartTx #LungTx #TransplantSky #MedSky

Evolocumab's Impact on Coronary Physiology on JHLT: The Podcast The JHLT team discusses a study from Aarhus University Hospital in Denmark on the impact evolocumab may have on coronary physiology and microstructure in de-novo heart transplant recipients.

On today's #JHLT podcast, Salma Karim and Hans Eiskjær of @au.dk Hospital join early career guest host Bin Yang of Mass General in Boston to discuss the impact of #evolocumab on coronary physiology and microstructure in heart transplant.

#cardiosky #transplantsky #medsky

🚨 #CallforPapers: Submit your papers on Primary Graft Dysfunction (PGD) in thoracic organ #transplantation to @jhlt.bsky.social. 🫀🫁 Submissions will be accepted until 📆 28 February: 🔗 bit.ly/4r6vuog

#PGD #JHLT #TransplantSky #MedSky

🚨 Submit your papers on device therapies for advanced #HeartDisease & #LungDisease to #JHLT. 🫀🫁 Submissions will be accepted until 📆 30 December: 🔗 https://bit.ly/48RJQBk

#TransplantSky #MedSky

Suspicious lung lesions in lung transplant patients on JHLT: The Podcast The JHLT Digital Media Editors host a discussion with senior author Stefan Schwarz, MD, PhD, on lung transplant patients with suspicious lung lesions.

Stefan Schwarz, MD, PhD, of @meduniwien.ac.at is on the #JHLT podcast to discuss #LungTransplant in patients w/suspicious lung lesions. What can we learn about standards in clinical practice from this discussion?

#pulmsky #transplantsky #medsky #oncsky

www.ishlt.org/about/news-d...

Donor-Specific Antibodies and the Development of BLAD on JHLT: The Podcast First author Muhtadi Alnababteh, MD, and senior author Michael Keller, MD, are on the podcast this month to discuss the impact of DSAs on longitudinal lung function and BLAD.

Today on the #JHLT podcast, Muhtadi Alnababteh and Michael Keller join to discuss their paper on #Donor-Specific antibodies, longitudinal lung function, and the development of #BLAD.

#PulmSky #TransplantSky #MedSky

www.ishlt.org/about/news-d...

JHLT: The Podcast: Cardiogenic Shock Working Group Nir Uriel, MD appears on JHLT: The Podcast to discuss the work of the Cardiogenic Shock Working Group and their recent paper on the outcomes of patients supported on Impella 5.5 .

On the #JHLT podcast last week, co-lead author Nir Uriel discussed the work of the Cardiogenic Shock Working Group and their recent paper on the outcomes of patients supported on Impella 5.5. Listen now!

#JHLTThePodcast #CardiogenicShock #CardioSky

www.ishlt.org/about/news-d...

JHLT The Podcast: Optimal Pre-Transplant Duration with HeartMate III LVADs Ahmet Bilgili and Eric Jeng, MD, of the University of Florida, are on JHLT the Podcast to discuss optimal pre-transplant duration for HeartMate III LVADs.

On #JHLTThePodcast: first author Ahmet Bilgili and senior author Eric Jeng of the University of Florida discuss the optimal pre- #HeartTx duration with the #HeartMate3 #LVAD.

Listen wherever you get your podcasts!

#JHLT #MCS #MechanicalCirculatorySupport

www.ishlt.org/about/news-d...

JHLT The Podcast: Metabolic insights on temperature controlled donor hearts Hear about how temperature storage affects donor hearts on a molecular level from Gaurav Sharma of the University of Texas Southwestern Medical Center on JHLT: The Podcast.

Today on #JHLTThePodcast: Gaurav Sharma, PhD, MBA joins to discuss #metabolic and #transcriptomic insights on #donorhearts with temperature controlled hypothermic preservation versus conventional static cold storage.

#JHLT #HeartTx #CardioSky #TransplantSky

www.ishlt.org/about/news-d...

📢Check out this issue of #JHLT wherein the crackerjack team At NYU highlights a gap in the current 🫀 allocation system. Anyone who has cared for a young patient with CAV knows this pain.

t.co/Slbb4jLT6h

Goodnight Moon, The (not so) Mystical Effect of Folklore and Superstitions on Cardiac Transplantation Do Friday the 13ths or Full Moons negatively impact heart transplants? Does volume increase on these "unlucky" days? Slide shows study design and findings, which can be read at the link in the post.

Happy #FridayThe13th - and if you're transplanting, fear not! This research group found no superstitious effect of Friday the 13ths or Full Moons on cardiac transplant outcomes, acuity, and volume.

#JHLT #heartTx #cardiosky #transplantsky @uofpenn.bsky.social

www.jhltonline.org/article/S105...

Pragmatic approach to temporary mechanical circulatory support in acute right ventricular failure Acute right ventricular failure (RVF) is prevalent in multiple disease states and is associated with poor clinical outcomes. Right-sided temporary mechanical circulatory support (tMCS) devices are used to unload RV congestion and increase cardiac output in cardiogenic shock (CS) with hemodynamically significant RVF. Several RV-tMCS device platforms are available; however consensus is lacking on patient selection, timing of escalation to RV-tMCS, device management, and device weaning. The purposes of this review are to 1) describe the current state of tMCS device therapies for acute RVF with CS, 2) discuss principles of escalation to RV-tMCS device therapy, 3) examine important aspects of clinical management for patients supported by RV-tMCS devices including volume management, anticoagulation, and positive pressure ventilation, and 4) provide a framework for RV-tMCS weaning.

www.jhltonline.org/article/S105...

#JHLT Superb “State of art” on RV tMCS devices for RV / BiV shock.

I hope they join bluesky soon Navin Kapur, Manreet Kanwar!